These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 25792732)

  • 41. Vorapaxar (Zontivity) for the Prevention of Thrombotic Cardiovascular Events.
    Barry KA; Somerville NJ
    Am Fam Physician; 2015 Aug; 92(4):304-5. PubMed ID: 26280236
    [No Abstract]   [Full Text] [Related]  

  • 42. Overview of the 2014 Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee meeting about vorapaxar.
    Baker NC; Lipinski MJ; Lhermusier T; Waksman R
    Circulation; 2014 Oct; 130(15):1287-94. PubMed ID: 25287768
    [No Abstract]   [Full Text] [Related]  

  • 43. Vorapaxar, a Protease-Activated Receptor-1 Antagonist, a Double-Edged Sword!
    Bhandari B; Mehta B
    Recent Adv Cardiovasc Drug Discov; 2014; 9(2):73-7. PubMed ID: 26104312
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Protease-activated receptor 1-selective antagonist SCH79797 inhibits cell proliferation and induces apoptosis by a protease-activated receptor 1-independent mechanism.
    Di Serio C; Pellerito S; Duarte M; Massi D; Naldini A; Cirino G; Prudovsky I; Santucci M; Geppetti P; Marchionni N; Masotti G; Tarantini F
    Basic Clin Pharmacol Toxicol; 2007 Jul; 101(1):63-9. PubMed ID: 17577318
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discovery of Potent Orally Active Protease-Activated Receptor 1 (PAR1) Antagonists Based on Andrographolide.
    Liu J; Sun B; Zhao X; Xing J; Gao Y; Chang W; Ji J; Zheng H; Cui C; Ji A; Lou H
    J Med Chem; 2017 Aug; 60(16):7166-7185. PubMed ID: 28745507
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Protease activated receptor-1 antagonist ameliorates the clinical symptoms of experimental autoimmune encephalomyelitis via inhibiting breakdown of blood-brain barrier.
    Kim HN; Kim YR; Ahn SM; Lee SK; Shin HK; Choi BT
    J Neurochem; 2015 Nov; 135(3):577-88. PubMed ID: 26285165
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Protease-Activated Receptors 1 and 3 are Differentially Expressed on Human Monocyte Subsets and are Upregulated by Lipopolysaccharide Ex Vivo and In Vivo.
    Thaler B; Hohensinner PJ; Baumgartner J; Haider P; Krychtiuk KA; Schörgenhofer C; Jilma B; Hell L; Fischer MB; Huber K; Hengstenberg C; Speidl WS; Wojta J
    Thromb Haemost; 2019 Sep; 119(9):1394-1402. PubMed ID: 31291665
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Discovery of potent peptide-mimetic antagonists for the human thrombin receptor, protease-activated receptor-1 (PAR-1).
    Maryanoff BE; Zhang HC; Andrade-Gordon P; Derian CK
    Curr Med Chem Cardiovasc Hematol Agents; 2003 Mar; 1(1):13-36. PubMed ID: 15317288
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A novel protease-activated receptor 1 inhibitor from the leech Whitmania pigra.
    Ren SH; Liu ZJ; Cao Y; Hua Y; Chen C; Guo W; Kong Y
    Chin J Nat Med; 2019 Aug; 17(8):591-599. PubMed ID: 31472896
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Protease-activated receptors differentially regulate human platelet activation through a phosphatidic acid-dependent pathway.
    Holinstat M; Voss B; Bilodeau ML; Hamm HE
    Mol Pharmacol; 2007 Mar; 71(3):686-94. PubMed ID: 17151288
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRA*CER) trial: study design and rationale.
    TRA*CER Executive and Steering Committees
    Am Heart J; 2009 Sep; 158(3):327-334.e4. PubMed ID: 19699853
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Octahydrocyclopenta[c]pyridine and octahydrocyclopenta[c]pyran analogues as a protease activated receptor 1 (PAR1) antagonist.
    Wadood A; Kim H; Park CM; Song JH; Lee S
    Arch Pharm Res; 2015 Nov; 38(11):2029-41. PubMed ID: 26068939
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes. The TRACER Pharmacodynamic Substudy.
    Storey RF; Kotha J; Smyth SS; Moliterno DJ; Rorick TL; Moccetti T; Valgimigli M; Dery JP; Cornel JH; Thomas GS; Huber K; Harrington RA; Hord E; Judge HM; Chen E; Strony J; Mahaffey KW; Tricoci P; Becker RC; Jennings LK
    Thromb Haemost; 2014 May; 111(5):883-91. PubMed ID: 24402559
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Challenges and promises of developing thrombin receptor antagonists.
    Yang J; Xu K; Seiffert D
    Recent Pat Cardiovasc Drug Discov; 2010 Nov; 5(3):162-70. PubMed ID: 20874673
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Safety of the novel protease-activated receptor-1 antagonist vorapaxar in Japanese patients with a history of ischemic stroke.
    Shinohara Y; Goto S; Doi M; Jensen P
    J Stroke Cerebrovasc Dis; 2012 May; 21(4):318-24. PubMed ID: 20947374
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vorapaxar in the secondary prevention of atherothrombotic events.
    Morrow DA; Braunwald E; Bonaca MP; Ameriso SF; Dalby AJ; Fish MP; Fox KA; Lipka LJ; Liu X; Nicolau JC; Ophuis AJ; Paolasso E; Scirica BM; Spinar J; Theroux P; Wiviott SD; Strony J; Murphy SA;
    N Engl J Med; 2012 Apr; 366(15):1404-13. PubMed ID: 22443427
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Using PAR4 Inhibition as an Anti-Thrombotic Approach: Why, How, and When?
    Li S; Tarlac V; Hamilton JR
    Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717963
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Protease-activated receptor-3 (PAR3) regulates PAR1 signaling by receptor dimerization.
    McLaughlin JN; Patterson MM; Malik AB
    Proc Natl Acad Sci U S A; 2007 Mar; 104(13):5662-7. PubMed ID: 17376866
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Investigating detailed interactions between novel PAR1 antagonist F16357 and the receptor using docking and molecular dynamic simulations.
    Readmond C; Wu C
    J Mol Graph Model; 2017 Oct; 77():205-217. PubMed ID: 28881236
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Evolving Concept of Neuro-Thromboinflammation for Neurodegenerative Disorders and Neurotrauma: A Rationale for PAR1-Targeting Therapies.
    Festoff BW; Dockendorff C
    Biomolecules; 2021 Oct; 11(11):. PubMed ID: 34827556
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.